Page 59 - Formulation News Today

Is, because i know we desperately want the opportunity to celebrate. but just on the hospitalizations, kate, thank goodness were not seeing the levels that weve seen in previous surges, but the numbers are ticking up and health care workers are exhausted and dep depleted. were understaffed in our hospitals. the antibodies were using dont work on this variant. there is a new formulation that does which we dont have yet in supply in new york, and really hospitals have stopped using the anticlonals...

We need them to solve the bottleneck in the lab facility so it doesnt take three to four days to get results back, and while hospitalizations are not moving as fast as cases are, thank goodness now, thats also ticking up in new york city, and we have resource channels there as well. the monoclonal antibodies that weve been using for delta dont work with omicron, and the new formulations that are going to work going forward are in short supply. basically hospitals in new york city have stopped of...

A plan forms in Mexico: Help Americans get abortions

The pharmaceutical company has announced GMP-related challenges with a manufacturer contracted to fill syringes for Wegovy pens headed to the US market.

In this 2021 round-up, we’re featuring the biggest cosmetic science stories of the year.

Below are the top 10 most read articles on ingredients and formulation on CosmeticsDesign this year.

An ingredient commonly isolated from soybeans, peanuts, and egg yolks, has been shown in a recent review to act in similar pathways as cannabidiol (CBD), with researchers highlighting that it was a safer and legally recognised alternative.

The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.

Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, received approval for AVT02 (100

Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.